Clinical trials: High Risk Prostate Cancer
Prostatic Carcinoma
Imaging of High Grade Prostate Cancer
Management of prostatic carcinoma varies according to stage of disease. Trans-rectal ultrasound guided biopsy is known to underestimate the degree of tumor due to undersampling and random non-targeted technique.
- Trial name
- NCT02177526
- Testing
- Imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Benign Prostate Hyperplasia
Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers
This is a multicenter, cohort study based on medico-administrative data from pathology laboratory registries and drug reimbursement files (CNAM-TS).
- Trial name
- CANARI (NCT02873117)
- Testing
- Prostate biopsy, prostatectomy or prostate resection
- Where
- France
- Volunteers
- 5,154 people
- Sponsor
- Rennes University Hospital
Prostate Adenocarcinoma, Stage I Prostate Cancer
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02346253
- Testing
- Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Stanford University
Prostate Cancer, Quality of Life
Functional Outcomes and QoL in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by RARP
The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This database investigates the status after robot assisted laparoscopic prostatectomy (RALP) in prostate cancer patients.
- Conditions
- Prostate Cancer, Quality of Life, Erectile Function, Urinary Function
- Trial name
- NCT03790995
- Testing
- Robot assisted laparoscopic prostatectomy
- Where
- 25 sites in Belgium
- Volunteers
- 9,235 people
- Sponsor
- KU Leuven
Prostate Cancer
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
This is a phase I study to evaluate the feasibility and safety of using MRI/MRS to identify the dominant intraprostatic lesion (DIL) and to selectively boost the lesion using inverse planned high dose rate (HDR) brachytherapy.
- Trial name
- NCT00807820
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Prostatic Neoplasms, Neoplasm Metastasis
Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients
For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery.
- Trial name
- NCT04790968
- Testing
- PSMA-PET, PSMA-PET/MRI, PSMA-PET/CT
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Norwegian University of Science and Technology
Prostatic Neoplasms
Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer
The purpose of this study is to determine whether adjuvant radiotherapy following radical prostatectomy in prostate cancer patients with positive margins or capsular penetration improves biochemical, overall and/or cancer…
- Trial name
- NCT02668718
- Testing
- Adjuvant radiotherapy
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Prostate Cancer
High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer
RATIONALE: High-intensity focused ultrasound ablation uses high-energy sound waves to kill tumor cells. PURPOSE: This phase II trial is studying the side effects of high-intensity focused ultrasound ablation and to see how well…
- Trial name
- NCT00987675
- Testing
- pharmacological study, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College London Hospitals
Prostatic Neoplasms
Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose
3-D conformal radiotherapy offers the opportunity to reach higher tumor doses with acceptable complication rates compared to conventional radiotherapy.
- Trial name
- NCT00692107
- Testing
- Gray
- Where
- 4 sites in Netherlands
- Volunteers
- 669 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00023829
- Testing
- bicalutamide, flutamide, releasing hormone agonist therapy
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer
This phase II randomized controlled study aims to compare the treatment results of intermediate and high risk prostate cancer patients treated with hormonal therapy and radical radiotherapy with or without pelvic lymph nodes in…
- Trial name
- NCT05285319
- Testing
- Prostate Only Radiation, Prostate and Pelvic Lymph Node Radiation
- Where
- Egypt
- Volunteers
- 82 people
- Sponsor
- Cairo University
Prostate Cancer
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical…
- Trial name
- CAP (NCT00132301)
- Testing
- Docetaxel, Prednisone
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer
Post-operative or Early Salvage XRT and ADT for High Risk PCa
RATIONALE: Conformal radiation therapy uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor.
- Trial name
- NCT00949962
- Testing
- antiandrogen therapy, leuprolide acetate, 3-dimensional conformal radiation therapy
- Where
- France
- Volunteers
- 87 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
One of the biggest problems facing prostate cancer patients and their treating physicians is who needs to be treated and when. Common clinical and pathological parameters are useful (PSA, Gleason score, etc.) but do not clearly…
- Trial name
- NCT01350180
- Where
- 8 sites in Canada
- Sponsor
- Dr. Tamim Niazi
Prostate Cancer
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.
- Trial name
- NCT00500110
- Testing
- Docetaxel, Imatinib Mesylate, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate
Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate
The purpose of this study is to determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer.
- Trial name
- NCT00915122
- Testing
- Dose Escalated IMRT
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Prostatic Neoplasms
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
The purpose of this study is to see if sequence inversion of Intensity - modulated Radiotherapy (IMRT) for prostate cancer, can improve the safety and deliverability of concurrent docetaxel chemotherapy with long - term hormonal…
- Trial name
- NCT00452556
- Testing
- Docetaxel, Leuprolide Acetate (Eligard®), Intensity-Modulated Radiotherapy
- Where
- Canada
- Volunteers
- 86 people
- Sponsor
- Nova Scotia Cancer Centre